Clinical Trials Browser

INDUSTRY × Interventional × Lisaftoclax × Clear all

NCT05147467 2026-03-27

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06389292 2025-11-25

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04496349 2025-11-04

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Prolymphocytic, T-Cell

NCT04501120 2025-09-26

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04260217 2025-08-19

MAPLE-1

Phase 1 Completed

Waldenstrom Macroglobulinemia

NCT03913949 2025-04-16

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04494503 2025-04-16

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05701306 2025-02-25

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Phase 1 Recruiting

Neuroblastoma

NCT03537482 2024-08-19

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Phase EARLY_PHASE1 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04946864 2024-08-19

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Phase 1/2 Suspended

Breast Neoplasms

NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Amyloidosis, Multiple Myeloma

NCT04964518 2023-10-25

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Phase 1/2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04674514 2023-03-07

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma